Drugs Safety Labeling Updates
Drugs Safety Labeling Updates
| Scientific Name | Trade Name | Updated Section | Safety-Related Labeling Changes | Date |
|---|---|---|---|---|
| Omeprazole | Aciloc | 4.5 Interaction with other medicinal products and other forms of interaction | Drugs which induce CYP2C19 or CYP3A4 (such as St. John’s Wort or rifampin) can substantially decrease omeprazole concentrations. | Mar, 2025 |
| M.M.R II | M.M.R II | 4.5 Interaction with other medicinal products and other forms of interaction | Concomitant administration with other vaccines | Mar, 2025 |
| Abrocitinib | Cibinqo | 6.6 Special precautions for disposal | Keep out of reach and sight of children. | Mar, 2025 |
| Prednisolone Acetate | Pred Forte | 4.8 Undesirable effects | Visual disturbance may be reported with systemic and topical corticosteroid use | Feb, 2025 |
| Telmisartan | Micardis | 4.4 Special warnings and precautions for use. 4.8 Undesirable effects | Intestinal angioedema | Feb, 2025 |
| Tucatinib | Tukysa | 4.4 Special warnings and precautions for use | Prompt medical management should also be instituted in the event of persistence of concomitant Grade 2 diarrhoea with concomitant Grade ≥2 nausea and/or vomiting. | Feb, 2025 |